BeiGene Greater China News and Activities
Presence
Headquarters: China
BeOne Medicines is one of the...
BeOne Medicines is a company listed under the stock ticker 688235 (HK).
BeOne Medicines has a direct presence in 2 countries.
They are in:
- Biotechnology67%
- Pharmaceuticals33%
Acquisition, funding and merger involving BeOne Medicines.
- BeOne Medicines has just announced a $885 Million fundraising (posted on August 28 2025).
- BeiGene will change its company name to BeOne Medicines. (posted on November 15 2024).
Executives
View the org chart displaying its 5 main executives
Most searched biographies at BeiGene Greater China
- Xiaobin Wu, President
- Eva Yin, Chief Commercial Officer
- Yong Cao, Vice President, Business Development
Popular executive movements at BeOne Medicines
- Corsee Sanders, Director, has left the company (posted on June 12 2026).
- Ranjeev Krishana, Director, has left the company (posted on June 12 2026).
- Michael Goller, Director, has left the company (posted on June 12 2026).
Click here to view some more movements at BeOne Medicines
Create your alert
to follow the executive moves at BeiGene Greater China.
Biotechnology
BeOne Medicines has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by BeiGene Greater China
Social media about BeiGene Greater China
- BeiGene Greater China on Wikipedia, Google News & Yahoo Finance
- BeiGene Greater China on LinkedIn, X (Twitter) & YouTube
